Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Yvonne Voges"'
Autor:
Martin Michaelis, Mark N. Wass, Ian Reddin, Yvonne Voges, Florian Rothweiler, Stephanie Hehlgans, Jaroslav Cinatl, Marco Mernberger, Andrea Nist, Thorsten Stiewe, Franz Rödel, Jindrich Cinatl Jr.
Publikováno v:
Cancers
Cancers, Vol 12, Iss 1080, p 1080 (2020)
Cancers, Vol 12, Iss 1080, p 1080 (2020)
Survivin is a drug target and its suppressant YM155 a drug candidate mainly investigated for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d38c5c70b66e4827c343f4079d72ea91
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54471
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54471
Autor:
Yvonne Voges, Franz Rödel, Mark N. Wass, Andreas von Deimling, Fabian Weipert, Florian Rothweiler, Jaroslav Cinatl, Jindrich Cinatl, Martin Michaelis, Amara Zia-Ahmad, Frank Westermann
Publikováno v:
Cancers, Vol 12, Iss 3, p 577 (2020)
Cancers
Volume 12
Issue 3
Cancers
Volume 12
Issue 3
The survivin suppressant YM155 is a drug candidate for neuroblastoma. Here, we tested YM155 in 101 neuroblastoma cell lines (19 parental cell lines, 82 drug-adapted sublines). 77 cell lines displayed YM155 IC50s in the range of clinical YM155 concent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77d6fde123f5346d5f44ae77c77a6414
https://www.mdpi.com/2072-6694/12/3/577
https://www.mdpi.com/2072-6694/12/3/577
Autor:
Jaroslav Cinatl, Yvonne Voges, Andrea Nist, Martin Michaelis, Ian G. Reddin, Franz Roedel, Marco Mernberger, Stephanie Hehlgans, Jindrich Cinatl, Mark N. Wass, Florian Rothweiler, Thorsten Stiewe
Survivin is a drug target and the survivin suppressant YM155 a drug candidate for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 efflux) leve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adbe7f03fda2ad7557452d07e7816108
Publikováno v:
Mutation research.
Nickel metal is a naturally occurring element used in many industrial and consumer applications. Human epidemiological data and animal cancer bioassays indicate that nickel metal is not likely to be a human carcinogen. Yet, nickel metal is classified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::780b7d11187f8594344aaa97e2d67398
https://pubmed.ncbi.nlm.nih.gov/32014793
https://pubmed.ncbi.nlm.nih.gov/32014793
Autor:
Mark N. Wass, Marco Mernberger, Martin Michaelis, Andrea Nist, Constanze Schneider, Jindrich Cinatl, Franz Rödel, Torsten Schaller, Thorsten Stiewe, Katharina Politt, Florian Rothweiler, Yvonne Voges
Publikováno v:
Cell Death & Disease
Resistance formation after initial therapy response (acquired resistance) is common in high-risk neuroblastoma patients. YM155 is a drug candidate that was introduced as a survivin suppressant. This mechanism was later challenged, and DNA damage indu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f081311ed9eb71d5f0c36923acfe3f80
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45758
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45758
Autor:
Yvonne Voges, Barbora Balónová, Martin Michaelis, Florian Rothweiler, Jindrich Cinatl, Nadine Löschmann, Barry A. Blight
Publikováno v:
Oncotarget
The CDK inhibitor SNS-032 had previously exerted promising anti-neuroblastoma activity via CDK7 and 9 inhibition. ABCB1 expression was identified as major determinant of SNS-032 resistance. Here, we investigated the role of ABCB1 in acquired SNS-032
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e12af6ae17cc8742916edaf1046ad9aa
Autor:
Yvonne Voges, R. Florian, Nadine Löschmann, J. Cinatl, Mark N. Wass, Frank Westermann, Martin Michaelis, Bishr Agha
Publikováno v:
European Journal of Cancer. 69:S47
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5096ffcd0403f3cd8672f8a4acb1be2a
https://doi.org/10.1016/s0959-8049(16)32725-3
https://doi.org/10.1016/s0959-8049(16)32725-3
Autor:
A. von Deimling, J. Cinatl, Yvonne Voges, Franz Rödel, Rainer Breitling, Florian Rothweiler, Nadine Löschmann, Daniel Speidel, Susanne Barth, Martin Michaelis, H. Wilhelm Doerr, Bishr Agha
Publikováno v:
Cell death & disease, 3(4):294. Nature Publishing Group
Cell Death & Disease
Cell Death & Disease
Adaptation of wild-type p53 expressing UKF-NB-3 cancer cells to the murine double minute 2 inhibitor nutlin-3 causes de novo p53 mutations at high frequency (13/20) and multi-drug resistance. Here, we show that the same cells respond very differently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0adf9e0b18e1314ddcf611cdf88671c
https://research.rug.nl/en/publications/f013404e-63c6-4cac-a489-35fee0a3aafc
https://research.rug.nl/en/publications/f013404e-63c6-4cac-a489-35fee0a3aafc
Autor:
Taravat Ghafourian, Yvonne Voges, Richard Zehner, Andreas von Deimling, Mohsen Sharifi, Nadine Löschmann, Iduna Fichtner, Frank Westermann, Jochen Meyer, Martin Michaelis, Florian Rothweiler, Jaroslav Cinatl, Kristoffer Riecken, Jindrich Cinatl
Publikováno v:
Translational Oncology. 6:685-IN18
Novel treatment options are needed for the successful therapy of patients with high-risk neuroblastoma. Here, we investigated the cyclin-dependent kinase (CDK) inhibitor SNS-032 in a panel of 109 neuroblastoma cell lines consisting of 19 parental cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1389d51f640e9b6834c83d8e25806795
https://doi.org/10.1593/tlo.13544
https://doi.org/10.1593/tlo.13544
Autor:
Mary, Y. Shyma1 (AUTHOR), Kumar, Veena S.2,3 (AUTHOR), Mary, Y. Sheena1 (AUTHOR), K. S., Resmi1 (AUTHOR), Thomas, Renjith4 (AUTHOR)
Publikováno v:
Polycyclic Aromatic Compounds. 2022, Vol. 42 Issue 5, p2581-2590. 10p.